Salvatore Siena
Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.
Overview
Salvatore Siena is professor of medical oncology at the University of Milan and led the Niguarda Cancer Center's oncology programme. He was a senior investigator of HERACLES and first author of the 2021 Lancet Oncology report of DESTINY-CRC01, the phase 2 trial in which trastuzumab deruxtecan produced responses in HER2-positive, RAS wild-type metastatic colorectal cancer after standard therapy. He was also a lead investigator of the panitumumab trials that established RAS testing before anti-EGFR treatment.
Similar pages
not linked directly; found by shared links- PersonAndrea Sartore-Bianchi
Shares Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, HERACLES, HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonJohn H. Strickler
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonRona Yaeger
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonGerald W. Prager
Shares Colorectal cancer and the tags colorectal, trialist.
- PersonScott Kopetz
Shares Colorectal cancer and the tags colorectal, targeted-therapy.
- PersonAleksandar Sekulic
Shares the tags targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares the tags targeted-therapy, trialist.
- PersonEric Jonasch
Shares the tags targeted-therapy, trialist.